openPR Logo
Press release

Pheochromocytomas Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bausch Health and Ono Pharma, Shionogi, Nippon Kayaku, Kyowa Hakko Kirin, Chimerix

02-12-2025 07:53 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Pheochromocytomas Market Statistics Expected to Experience

DelveInsight's "Pheochromocytomas Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pheochromocytomas, historical and forecasted epidemiology as well as the Pheochromocytomas market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Pheochromocytomas, offering comprehensive insights into the Pheochromocytomas revenue trends, prevalence, and treatment landscape. The report delves into key Pheochromocytomas statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Pheochromocytomas therapies. Additionally, we cover the landscape of Pheochromocytomas clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Pheochromocytomas treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Pheochromocytomas space.

To Know in detail about the Pheochromocytomas market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pheochromocytomas Market Forecast
https://www.delveinsight.com/sample-request/pheochromocytoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pheochromocytomas Market Report:
• The Pheochromocytomas market size was valued ~USD 350 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2024, Perspective Therapeutics revealed that the US FDA has selected its investigational product [212Pb]VMT-a-NET for the treatment of specific neuroendocrine tumor patients to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.
• In November 2023, Enterome announced that it will present immune-monitoring data from the ongoing EO2401 trials in adrenal tumors and recurrent glioblastoma at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting.
• The treatment landscape for metastatic PCPG has seen both progress and obstacles. Although curative treatments are not yet available, patients are managed through a multidisciplinary approach that includes debulking surgery, chemotherapy (e.g., the CVD regimen with cyclophosphamide, dacarbazine, and vincristine), tyrosine kinase inhibitors, immunotherapies, and radionuclide therapy with 177Lu-DOTATATE.
• The total market size for PCPG in the US was estimated at USD 200 million in 2023, and it is anticipated to grow with the introduction of new therapies.
• In 2023, MIBG accounted for a market size of around USD 10 million for PCPG therapies in Japan.
• Key Pheochromocytomas Companies: Bausch Health and Ono Pharmaceutical, Shionogi, Nippon Kayaku, Kyowa Hakko Kirin, Chimerix, Merck Sharp & Dohme, Advanced Accelerator Applications, Enterome, Perspective Therapeutics, and others.
• Key Pheochromocytomas Therapies: DEMSER Capsule 250 mg (metyrosine), ENDOXAN (cyclophosphamide hydrate), ONCOVIN (vincristine Sulfate), Dacarbazine Injection, ONC201, Belzutifan/MK-6482, LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), EO2401 combination with nivolumab, VMT-𝛼-NET, and others
• The Pheochromocytomas market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pheochromocytomas pipeline products will significantly revolutionize the Pheochromocytomas market dynamics.
• In 2023, the total number of new cases of PCPG across the 7MM was approximately 4,800, and this figure is expected to rise throughout the forecast period.
• In 2023, it was noted that germline or somatic mutations are found in almost 75% of cases in the US.
• In 2023, the estimated number of new PCPG cases in the EU4 and the UK was approximately 1,800.

Pheochromocytomas Overview
Pheochromocytomas are rare tumors that develop in the adrenal glands, leading to excessive production of catecholamines (adrenaline and noradrenaline). These tumors can cause high blood pressure, rapid heart rate, sweating, and headaches. While mostly benign, some can be malignant and may spread to other organs. Diagnosis involves biochemical tests and imaging, and treatment typically includes surgical removal, often preceded by medication to manage blood pressure.

Get a Free sample for the Pheochromocytomas Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/pheochromocytoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pheochromocytomas Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pheochromocytomas Epidemiology Segmentation:
The Pheochromocytomas market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Pheochromocytomas
• Prevalent Cases of Pheochromocytomas by severity
• Gender-specific Prevalence of Pheochromocytomas
• Diagnosed Cases of Episodic and Chronic Pheochromocytomas

Download the report to understand which factors are driving Pheochromocytomas epidemiology trends @ Pheochromocytomas Epidemiology Forecast
https://www.delveinsight.com/sample-request/pheochromocytoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pheochromocytomas Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pheochromocytomas market or expected to get launched during the study period. The analysis covers Pheochromocytomas market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pheochromocytomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pheochromocytomas Therapies and Key Companies
• DEMSER Capsule 250 mg (metyrosine): Bausch Health and Ono Pharmaceutical
• ENDOXAN (cyclophosphamide hydrate): Shionogi
• ONCOVIN (vincristine Sulfate): Nippon Kayaku
• Dacarbazine Injection: Kyowa Hakko Kirin
• ONC201: Chimerix
• Belzutifan/MK-6482: Merck Sharp & Dohme
• LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate): Advanced Accelerator Applications
• EO2401 combination with nivolumab: Enterome
• VMT-𝛼-NET: Perspective Therapeutics

Discover more about therapies set to grab major Pheochromocytomas market share @ Pheochromocytomas Treatment Landscape
https://www.delveinsight.com/sample-request/pheochromocytoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pheochromocytomas Market Drivers
• Increasing Incidence and Awareness
• Advancements in Genetic Research
• Innovative Treatment Development
• Improved Diagnostic Tools
• Rising Healthcare Investment
• Patient Advocacy and Awareness

Pheochromocytomas Market Barriers
• Limited Treatment Options
• High Treatment Costs
• Diagnostic Challenges
• Lack of Large-Scale Clinical Trials
• Healthcare Access Disparities
• Complexity of Management

Scope of the Pheochromocytomas Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pheochromocytomas Companies: Bausch Health and Ono Pharmaceutical, Shionogi, Nippon Kayaku, Kyowa Hakko Kirin, Chimerix, Merck Sharp & Dohme, Advanced Accelerator Applications, Enterome, Perspective Therapeutics, and others
• Key Pheochromocytomas Therapies: DEMSER Capsule 250 mg (metyrosine), ENDOXAN (cyclophosphamide hydrate), ONCOVIN (vincristine Sulfate), Dacarbazine Injection, ONC201, Belzutifan/MK-6482, LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), EO2401 combination with nivolumab, VMT-𝛼-NET, and others
• Pheochromocytomas Therapeutic Assessment: Pheochromocytomas current marketed and Pheochromocytomas emerging therapies
• Pheochromocytomas Market Dynamics: Pheochromocytomas market drivers and Pheochromocytomas market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pheochromocytomas Unmet Needs, KOL's views, Analyst's views, Pheochromocytomas Market Access and Reimbursement

To know more about Pheochromocytomas companies working in the treatment market, visit @ Pheochromocytomas Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/pheochromocytoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pheochromocytomas Market Report Introduction
2. Executive Summary for Pheochromocytomas
3. SWOT analysis of Pheochromocytomas
4. Pheochromocytomas Patient Share (%) Overview at a Glance
5. Pheochromocytomas Market Overview at a Glance
6. Pheochromocytomas Disease Background and Overview
7. Pheochromocytomas Epidemiology and Patient Population
8. Country-Specific Patient Population of Pheochromocytomas
9. Pheochromocytomas Current Treatment and Medical Practices
10. Pheochromocytomas Unmet Needs
11. Pheochromocytomas Emerging Therapies
12. Pheochromocytomas Market Outlook
13. Country-Wise Pheochromocytomas Market Analysis (2019-2032)
14. Pheochromocytomas Market Access and Reimbursement of Therapies
15. Pheochromocytomas Market Drivers
16. Pheochromocytomas Market Barriers
17. Pheochromocytomas Appendix
18. Pheochromocytomas Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Non-hodgkin's Lymphoma Market: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pheochromocytomas Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Bausch Health and Ono Pharma, Shionogi, Nippon Kayaku, Kyowa Hakko Kirin, Chimerix here

News-ID: 3865722 • Views:

More Releases from DelveInsight Business Research

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Poised for Transformation with FDA Approvals and Expanding Pipeline, Finds DelveInsight
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities in Dissolvable Microneedle Technology (dMTS) Space
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities i …
DelveInsight, a leading business consulting and market intelligence firm in healthcare, announces the release of its latest Competitive Landscape Assessment Case Study, showcasing opportunities in the dissolvable microneedle technology (dMTS) space. This in-depth analysis highlights how strategic evaluations and tailored solutions can enable global healthcare organizations to expand product offerings, secure intellectual property, and strengthen their competitive positions in the rapidly growing drug delivery market. Gain firsthand access to a complimentary
Competitive Intelligence in the Hematology Domain: Driving Strategic Success through Long-Term Engagement with DelveInsight
Competitive Intelligence in the Hematology Domain: Driving Strategic Success thr …
DelveInsight, a leader in healthcare consulting and competitive intelligence, has recently showcased its success in a long-term engagement for competitive intelligence support within the hematology domain. This case study highlights how timely, in-depth competitive intelligence empowered a Europe-based client to refine strategies, strengthen launch preparedness, and maintain a leadership position in the face of intense competition. The rapidly evolving field of hematological malignancies, including Acute Myeloid Leukemia (AML), Multiple Myeloma, and
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According to DelveInsight
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Pheochromocytomas

Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From …
Pheochromocytomas and Paragangliomas (PPGL) Market Outlook 2024-2034: Rising Awareness and Targeted Therapies Drive Growth Introduction Pheochromocytomas and paragangliomas (collectively known as PPGL or PCPG) are rare neuroendocrine tumors that originate from chromaffin cells in the adrenal medulla or extra-adrenal paraganglia. While pheochromocytomas arise in the adrenal glands, paragangliomas occur in various parts of the body including the abdomen, chest, and head-and-neck region. Although rare, these tumors can be life-threatening if untreated, often associated
Pheochromocytomas and Paragangliomas Market
Introduction Pheochromocytomas and Paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla (pheochromocytomas) or extra-adrenal ganglia (paragangliomas). These tumors often produce excess catecholamines, leading to hypertension, palpitations, headaches, and cardiovascular complications. While typically benign, a subset may become malignant, significantly complicating patient management. Historically, PPGLs have been underdiagnosed due to their nonspecific symptoms, but advances in genetic testing, imaging, and biochemical assays have improved detection. With
Pheochromocytomas and Paragangliomas Market Forecast - Unlocking Rare Tumor Insi …
Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors originating from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. While pheochromocytomas typically arise in the adrenal glands, paragangliomas can develop anywhere along the sympathetic and parasympathetic chains. Though generally benign, these tumors can secrete excess catecholamines, leading to severe cardiovascular complications such as hypertension, arrhythmias, and even stroke, if not diagnosed and managed promptly. DelveInsight's comprehensive report, "Pheochromocytomas and Paragangliomas
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from …
The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others. DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment
Pheochromocytomas and Paragangliomas Treatment Market Size in 7MM is expected to …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Pheochromocytomas and Paragangliomas, historical and forecasted epidemiology as well as the Pheochromocytomas and Paragangliomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the Pheochromocytomas and Paragangliomas Market Share @ Pheochromocytomas and Paragangliomas Market Outlook- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the
Pheochromocytomas and Paragangliomas Market Statistics Expected to Experience Ma …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pheochromocytomas and Paragangliomas, historical and forecasted epidemiology as well as the Pheochromocytomas and Paragangliomas market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Pheochromocytomas and Paragangliomas, offering comprehensive insights into the Pheochromocytomas and Paragangliomas revenue trends,